➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKinsey
Medtronic
Merck
Mallinckrodt

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

NADOLOL Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Nadolol patents expire, and when can generic versions of Nadolol launch?

Nadolol is a drug marketed by Amneal Pharms Co, Aurobindo Pharma Ltd, Beximco Pharms Usa, Heritage Pharma, Invagen Pharms, Lupin Ltd, Mylan, Novast Labs, Sandoz, Teva Pharms, Vgyaan, Zydus Pharms, and Impax Labs. and is included in fifteen NDAs.

The generic ingredient in NADOLOL is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.

Drug patent expirations by year for NADOLOL
Drug Prices for NADOLOL

See drug prices for NADOLOL

Drug Sales Revenue Trends for NADOLOL

See drug sales revenues for NADOLOL

Recent Clinical Trials for NADOLOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BioHealthonomics Inc.Phase 2
Emory UniversityPhase 4
Invion, Inc.Phase 2

See all NADOLOL clinical trials

Pharmacology for NADOLOL
Medical Subject Heading (MeSH) Categories for NADOLOL

US Patents and Regulatory Information for NADOLOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan NADOLOL AND BENDROFLUMETHIAZIDE bendroflumethiazide; nadolol TABLET;ORAL 078688-002 Feb 15, 2008 DISCN No No   Start Trial   Start Trial   Start Trial
Vgyaan NADOLOL nadolol TABLET;ORAL 212856-001 Sep 13, 2019 DISCN No No   Start Trial   Start Trial   Start Trial
Sandoz NADOLOL nadolol TABLET;ORAL 074501-003 Nov 9, 1995 AB RX No No   Start Trial   Start Trial   Start Trial
Vgyaan NADOLOL nadolol TABLET;ORAL 212856-002 Sep 13, 2019 DISCN No No   Start Trial   Start Trial   Start Trial
Teva Pharms NADOLOL nadolol TABLET;ORAL 074368-001 Aug 31, 1994 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Medtronic
McKesson
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.